Yao An | Thrombosis | Best Researcher Award

Posted on by Pencis

Mr. Yao An | Thrombosis | Best Researcher Award

Wei Eric Wang | Myocardial Infarction | Best Researcher Award

Posted on by Pencis

Prof. Wei Eric Wang | Myocardial Infarction | Best Researcher Award

Prof. Wei Eric Wang, Southwest Hospital, Army Medical University, China

Prof. Wei Eric Wang is a distinguished medical professional based at Southwest Hospital, Army Medical University, in China. Renowned for his expertise in medical research and clinical practice, he has contributed significantly to the fields of surgery, healthcare management, and medical education. With numerous publications in peer-reviewed journals, Prof. Wang has established a reputation for pioneering studies in his area of specialization. He is also actively involved in advancing medical training, and his leadership at the hospital continues to shape healthcare innovation in China. His work has earned him recognition both nationally and internationally.

AUTHOR PROFILE

Scopus

Orcid

🎓EARLY ACADEMIC PURSUITS:

Dr. Wei (Eric) Wang pursued his medical education at the Third Military Medical University in Chongqing, China. He earned his M.D. in Clinical Medicine from 2000 to 2005. Following this, he completed his Ph.D. at the Institute of Burn Surgery, Southwest Hospital, at the same university between 2005 and 2010. His early academic endeavors laid the foundation for his expertise in cardiology and geriatric medicine.

🏥PROFESSIONAL ENDEAVORS:

Dr. Wang has held various prestigious positions throughout his career. He has been the Director of the Department of Geriatrics at Southwest Hospital since November 2022, demonstrating his leadership in the field. Prior to this, he served as Chief Physician and Professor in the Department of Cardiology at Daping Hospital, Army Medical University. His extensive experience includes roles such as Deputy Director, Associate Chief Physician, Attending Doctor, and Resident, reflecting his progressive career growth and expertise in cardiology and geriatrics.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON Myocardial Infarction

Dr. Wang’s research is centered on new strategies for treating cardiovascular diseases, particularly myocardial infarction and heart failure. His primary areas of focus include:

  1. Mechanisms regulating cardiac regeneration.
  2. Translational and clinical studies for treating cardiovascular diseases.
  3. Translational and clinical research for preventing aging.

His work has significantly advanced the understanding of cardiac repair mechanisms and potential therapeutic interventions.

🌍IMPACT AND INFLUENCE:

Dr. Wang has played a crucial role in the field of cardiology and geriatrics. His research has contributed to innovative treatments that enhance cardiac regeneration and improve patient outcomes. As a leader in cardiovascular medicine, his influence extends beyond clinical practice to shaping future medical research and treatment methodologies.

📚ACADEMIC CITATIONS AND RECOGNITION:

Dr. Wang has an impressive list of publications in esteemed medical journals. Some of his notable works include:

  1. “Metabolic reprogramming: a byproduct or a driver of cardiomyocyte proliferation?” published in Circulation (2024).
  2. “Loss of NPPA-AS1 promotes heart regeneration by stabilizing SFPQ-NONO heteromer-induced DNA repair,” published in Basic Research in Cardiology (2022).
  3. “The Role of G Protein-Coupled Receptor Kinase 4 in Cardiomyocyte Injury after Myocardial Infarction,” published in European Heart Journal (2021).
  4. “Dedifferentiation, Proliferation, and Redifferentiation of Adult Mammalian Cardiomyocytes After Ischemic Injury,” published in Circulation (2017).

These publications highlight his extensive contributions to cardiovascular research and his role in advancing medical knowledge in this domain.

🌟LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Wang’s legacy is deeply rooted in his contributions to cardiovascular research, innovative treatment strategies, and leadership in geriatric medicine. As a distinguished professor and researcher, his work continues to shape the future of cardiology and geriatrics. His ongoing research and clinical innovations are expected to provide new breakthroughs in cardiac care and aging prevention, benefiting future generations of patients and medical professionals.

🚀CONCLUSION:

Prof. Wei Eric Wang is a distinguished cardiologist and geriatrician whose groundbreaking research and leadership have significantly impacted cardiovascular medicine. His dedication to innovation, patient care, and scientific discovery continues to inspire future generations. As Director of Geriatrics at Southwest Hospital, his work advances both clinical and translational medicine, improving lives worldwide. With numerous influential publications and a commitment to pioneering treatments, his contributions to cardiac regeneration and aging prevention are invaluable. His legacy in medicine and academia ensures a lasting impact, shaping the future of healthcare and research.

TOP NOTABLE PUBLICATIONS

  • Title: Metabolic Reprogramming: A Byproduct or a Driver of Cardiomyocyte Proliferation?
    Authors: Xiaokang Chen, Hao Wu, Ya Liu, Lingyan Liu, Steven R. Houser, Wei Eric Wang
    Journal: Circulation
    Year: 2024

  • Title: Loss of NPPA-AS1 promotes heart regeneration by stabilizing SFPQ–NONO heteromer-induced DNA repair
    Authors: Wenbin Fu, Hongmei Ren, Jialing Shou, Qiao Liao, Liangpeng Li, Yu Shi, Pedro A. Jose, Chunyu Zeng, Wei Eric Wang
    Journal: Basic Research in Cardiology
    Year: 2022

  • Title: The Protective Role of Yin‐Yang 1 in Cardiac Injury and Remodeling After Myocardial Infarction
    Authors: Yu Huang, Liangpeng Li, Hongmei Chen, Qiao Liao, Xiaoli Yang, Dezhong Yang, Xuewei Xia, Hongyong Wang, Wei Eric Wang, Lianglong Chen et al.
    Journal: Journal of the American Heart Association
    Year: 2021

  • Title: The role of G protein-coupled receptor kinase 4 in cardiomyocyte injury after myocardial infarction
    Authors: Wei Eric Wang, Liangpeng Li, Fu W, Gong X, Chen Z, Tang L, Yang D, Liao Q, Xia X, Wu H et al.
    Journal: European Heart Journal
    Year: 2021

  • Title: An Aurora Kinase B-Based Mouse System to Efficiently Identify and Analyze Proliferating Cardiomyocytes
    Authors: Wei Eric Wang, Fu W, Liao Q, Li L, Shi Y, Zeng A, Zeng C, Wang WE
    Journal: Frontiers in Cell and Developmental Biology
    Year: 2020

  • Title: Cardiomyocyte PKA Ablation Enhances Basal Contractility While Eliminates Cardiac β-Adrenergic Response Without Adverse Effects on the Heart
    Authors: Wei Eric Wang, Zhang Y, Wang WE, Zhang X, Li Y, Chen B, Liu C, Ai X, Zhang X, Tian Y et al.
    Journal: Circulation Research
    Year: 2019

  • Title: Noncoding RNA and Cardiomyocyte Proliferation
    Authors: Shuang Qu, Chunyu Zeng, Wei Eric Wang
    Journal: Stem Cells International
    Year: 2017

  • Title: Dedifferentiation, Proliferation, and Redifferentiation of Adult Mammalian Cardiomyocytes After Ischemic Injury
    Authors: Wei Eric Wang, Wang WE, Li L, Xia X, Fu W, Liao Q, Lan C, Yang D, Chen H, Yue R et al.
    Journal: Circulation
    Year: 2017

  • Title: Prolyl hydroxylase domain protein 2 silencing enhances the survival and paracrine function of transplanted adipose-derived stem cells in infarcted myocardium
    Authors: Wei Eric Wang, Wang WE, Yang D, Li L, Wang W, Peng Y, Chen C, Chen P, Xia X, Wang H et al.
    Journal: Circulation Research
    Year: 2013

Wang Yanqiang | Atherosclerosis | Best Researcher Award

Posted on by Pencis

Prof. Wang Yanqiang | Atherosclerosis | Best Researcher Award

Prof. Wang Yanqiang, Department of Neurology Ⅱ, The Affiliated Hospital of Shandong Second Medical University, China

Prof. Wang Yanqiang is a distinguished neurologist currently serving in the Department of Neurology II at the Affiliated Hospital of Shandong Second Medical University, China. With a strong academic background, Prof. Wang earned his Master’s degree in Neurology from Xu Zhou Medical University and a Ph.D. from Sun Yat-sen University. His research primarily focuses on the pathogenesis and neuroprotection of ischemic brain injury, Parkinson’s disease, and other cerebrovascular disorders. Over the years, Prof. Wang has held various key positions, including roles as a resident and attending doctor at leading medical institutions in China.

AUTHOR PROFILE

Orcid Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Wang Yanqiang began his academic journey in the field of neurology, focusing on understanding the intricacies of neurological disorders and brain function. He pursued his medical education and specialized in neurology, laying the foundation for his future contributions in this domain. His early academic training focused on acquiring deep knowledge of neurophysiology, clinical neurology, and neuroanatomy, which would later guide his professional endeavors.

🏥PROFESSIONAL ENDEAVORS:

Prof. Wang Yanqiang holds a distinguished position at the Department of Neurology II at The Affiliated Hospital of Shandong Second Medical University, China. Over the years, he has been a leading figure in both clinical practice and medical research. He has worked tirelessly in patient care, offering specialized neurological treatments and providing critical insights into various neurological conditions. His professional endeavors also include educating and mentoring students, fostering the next generation of neurologists, and playing a key role in advancing clinical practices within the medical community.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON Atherosclerosis

Prof. Wang Yanqiang’s research primarily revolves around neurological disorders, with a particular focus on neurodegenerative diseases, cerebrovascular disorders, and epilepsy. His contributions to the understanding of these diseases have led to significant advancements in both diagnostic techniques and treatment methodologies. His research also spans neuroplasticity, neuroinflammation, and neuroprotective strategies, aiming to develop better therapeutic approaches for patients suffering from neurological impairments. Additionally, Prof. Wang has contributed to the development of diagnostic tools that have improved clinical outcomes in neurology.

🌍IMPACT AND INFLUENCE:

Prof. Wang Yanqiang’s work has had a profound impact on the field of neurology in both China and internationally. His contributions to the understanding of complex neurological diseases have shaped modern clinical practices and research initiatives. His publications and research findings have influenced treatment protocols and inspired further studies in neurodegenerative and cerebrovascular diseases. As a prominent figure in neurology, Prof. Wang has served as a role model for younger neurologists, encouraging a new wave of innovative thinking and patient-centered care in neurology.

📚ACADEMIC CITATIONS AND RECOGNITION:

Prof. Wang Yanqiang’s research has been widely recognized and cited within the academic community. His articles and studies are frequently cited in major neurological journals, reflecting the significance of his work in advancing scientific knowledge in neurology. His contributions have earned him a reputation as a leading expert in the field, with many of his works becoming foundational references for ongoing research. His academic influence is evidenced not only by citations but also through his collaborations with prominent neurologists worldwide.

🌟LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Wang Yanqiang’s legacy in the field of neurology is marked by his groundbreaking research, dedication to patient care, and commitment to advancing the field. His work has contributed to a better understanding of neurological diseases and has paved the way for innovative treatments. As the field of neurology continues to evolve, Prof. Wang’s influence will likely continue to shape future developments in both clinical practice and medical research. His legacy also includes the mentorship of future generations of neurologists, ensuring that his impact on the field will extend far beyond his career.

🚀CONCLUSION:

Prof. Wang Yanqiang is an esteemed neurologist whose research has greatly advanced our understanding of ischemic brain injury, Parkinson’s disease, and cerebrovascular disorders. With a rich academic background and extensive clinical experience, his contributions to neuroprotection and molecular mechanisms are highly impactful. Through his numerous publications, Prof. Wang has gained international recognition for his work, which continues to influence the field of neurology. His dedication to improving patient outcomes and advancing neurological research makes him a true leader in the medical community.

TOP NOTABLE PUBLICATIONS

  • Title: Inhibition of the cGAS–STING pathway: contributing to the treatment of cerebral ischemia-reperfusion injury

    • Journal: Neural Regeneration Research
    • Volume: 2025-07
    • Year: 2025

  • Title: Exploring the Neuroprotective Effects of Lithium in Ischemic Stroke: A literature review

    • Journal: International Journal of Medical Sciences
    • Volume: 2024
    • Year: 2024

  • Title: Risk Factors and Clinical Characteristics of First-ever Ischemic Stroke Caused by ICAS with Leukoaraiosis

    • Journal: International Journal of Medical Sciences
    • Volume: 2024
    • Year: 2024

  • Title: 1,25-D3 ameliorates ischemic brain injury by alleviating endoplasmic reticulum stress and ferroptosis: Involvement of vitamin D receptor and p53 signaling

    • Journal: Cellular Signalling
    • Volume: 2024-10
    • Year: 2024

  • Title: A case of acute basilar artery occlusion due to atherosclerotic disease revascularized by drug-coated balloon dilation

    • Journal: International Journal of Neuroscience
    • Volume: 2024-09
    • Year: 2024

  • Title: A case report of drug-coated balloon dilation angioplasty in a patient with acute atherosclerotic basilar artery occlusion

    • Journal: Asian Journal of Surgery
    • Volume: 2024-09
    • Year: 2024

  • Title: Global, regional, and national epidemiology of ischemic stroke from 1990 to 2021

    • Journal: European Journal of Neurology
    • Volume: 2024-09-17
    • Year: 2024

  • Title: Genetic insights into the relationship between immune cell characteristics and ischemic stroke: A bidirectional Mendelian randomization study

    • Journal: European Journal of Neurology
    • Volume: 2024-05
    • Year: 2024

  • Title: Assessing tobacco-related ischemic stroke in Pakistan (1990-2019): Insights from the Global Burden of Disease Study

    • Journal: Tobacco Induced Diseases
    • Volume: 2024-03-28
    • Year: 2024

  • Title: First report of a p.Cys484Tyr Notch3 mutation in a CADASIL patient with acute bilateral multiple subcortical infarcts—case report and brief review

    • Journal: BMC Neurology
    • Year: 2024

Bing Li | Endocarditis | Best Researcher Award

Posted on by Pencis

Dr. Bing Li | Endocarditis | Best Researcher Award

Dr. Bing Li, Chinese PLA General Hospital First Medical Center, China

Dr. Bing Li is an Associate Chief Physician at The First Medical Center, Chinese PLA General Hospital, Beijing, China. He holds a Ph.D. in Endocrinology and Metabolism from PLA Medical College (2020) and has a Master’s Degree (2013) in the same field. His expertise includes diabetes, thyroid disorders, metabolic syndrome, and endocrine diseases. Dr. Li is actively involved in clinical practice, research, and medical education, contributing to advanced treatments and diagnostic techniques. His work has been published in leading medical journals, making a significant impact on endocrinology and metabolic disease management in China.

AUTHOR PROFILE

Scopus Profile

🎓EARLY ACADEMIC PURSUITS:

Dr. Bing Li’s academic journey began with a Bachelor’s Degree in Clinical Medicine from Hebei Medical University (2005–2010), where he laid the foundation for his expertise in the medical field. His passion for endocrinology and metabolism led him to pursue a Master’s Degree at PLA Medical College (2010–2013), further deepening his understanding of metabolic disorders and endocrine health. His dedication culminated in a Ph.D. in Endocrinology and Metabolism (2016–2020), where he focused on advanced research in hormonal and metabolic diseases.

🏥PROFESSIONAL ENDEAVORS:

Currently serving as an Associate Chief Physician at The First Medical Center, Chinese PLA General Hospital, Beijing, Dr. Li plays a crucial role in treating and managing complex endocrine disorders. His expertise spans diabetes, thyroid diseases, adrenal disorders, and metabolic syndromes, making him a key figure in China’s medical landscape.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON ENDOCARDITIS:

Dr. Li’s research primarily revolves around:

  • Diabetes and Insulin Resistance 🩸
  • Thyroid Disorders and Hormonal Imbalances 🦋
  • Adrenal and Pituitary Gland Diseases 🔄
  • Metabolic Syndrome and Obesity-Related Conditions ⚖️

His work aims to improve diagnostic techniques, enhance treatment protocols, and develop innovative therapeutic strategies for endocrine disorders. Through his research, he has contributed to clinical advancements in the management of metabolic diseases.

🌍IMPACT AND INFLUENCE:

Dr. Bing Li has made significant contributions to the Chinese medical community, particularly in endocrinology and metabolic medicine. As an Associate Chief Physician, he has influenced:

  • Clinical practices by integrating research-based solutions
  • Medical education through mentoring young doctors and researchers
  • Public health awareness on diabetes prevention and treatment

His work has helped shape medical guidelines and policies, ensuring improved patient outcomes in China and beyond.

📚ACADEMIC CITATIONS AND RECOGNITION:

Dr. Li’s scientific publications in high-impact medical journals have been widely cited by researchers and clinicians. His studies on endocrine disorders, metabolic regulation, and hormone-related diseases are highly regarded in the medical community.

🌟LEGACY AND FUTURE CONTRIBUTIONS:

With a strong foundation in endocrinology, Dr. Bing Li is set to expand his influence in medical research, clinical innovation, and public health policy. His future endeavors may include:
✅ Leading cutting-edge research in precision medicine for endocrine disorders
✅ Collaborating on international studies to enhance metabolic disease treatment
✅ Developing new medical technologies for early diagnosis and personalized therapy

Dr. Li’s dedication to medical excellence ensures that his legacy in endocrinology will continue to impact future generations of physicians and researchers.

🚀CONCLUSION:

Dr. Bing Li’s dedication to endocrinology and metabolic research has significantly impacted clinical practice, medical education, and patient care. His expertise in diabetes, thyroid disorders, and metabolic diseases continues to shape advanced treatments and innovative diagnostic approaches. As an Associate Chief Physician, he plays a vital role in improving healthcare outcomes in China. With his commitment to scientific progress and medical excellence, Dr. Li’s influence will extend to future generations of physicians and researchers. His work ensures better disease management, improved therapies, and enhanced patient well-being for years to come.

TOP NOTABLE PUBLICATIONS

Association Between Skin Autofluorescence and Coronary Heart Disease in Chinese General Population: A Cross-Sectional Study

Authors: Qingzheng Wu, Yu Cheng, Hongyan Liu, Bing Li, Yiming Mu

Journal: Journal of Diabetes

Year: 2025

The Efficacy and Safety of iGlarLixi versus IDegAsp in Chinese Patients with Type 2 Diabetes Suboptimally Controlled with Oral Antidiabetic Drugs: Interpretation of the Soli-D Study

Authors: Ming Liu, Weijun Gu, Li Chen, Yanbing Li, Hongyu Kuang, Jianling Du, Agustina Alvarez, Felipe Lauand, Elisabeth Souhami, Jiewen Zhang, Weiya Xu, Qin Du, Yiming Mu

Journal: Diabetes, Obesity & Metabolism

Year: 2024

Christina Antza | Hypertension | Best Research Article Award

Posted on by Pencis

Assist. Prof. Dr. Christina Antza | Hypertension | Best Research Article Award

Assist. Prof. Dr. Christina Antza, 3rd Department of Internal Medicine, Aristotle University of Thessaloniki, Greece

Assist. Prof. Dr. Christina Antza is a specialist in Internal Medicine and Hypertension at the 3rd Department of Internal Medicine, Aristotle University of Thessaloniki, Greece. She holds an M.D., a Ph.D. in blood pressure measurement methods, and an M.Sc. in Research Methodology. Dr. Antza has extensive experience in hypertension, metabolic syndrome, diabetes, and atherosclerosis. She has worked as a researcher, consultant, and medical educator in Greece and the UK. Recognized with multiple awards and fellowships, she actively contributes to international medical research and education, shaping advancements in cardiovascular and metabolic disease management.

AUTHOR PROFILE

Orcid Profile

🎓 EARLY ACADEMIC PURSUITS:

Dr. Christina Antza began her educational journey at the Fifth High-School of Drama (Junior High School) and Third High School of Drama (Senior High School). She then pursued her Medical Degree at Aristotle University of Thessaloniki, Greece (2007-2013), graduating with an impressive 8/10 grade.

Her passion for research and academia led her to further studies, including:

  • Ph.D. in Internal Medicine (2014-2019) – Focused on blood pressure measurement methods and their ability to predict early vascular aging. She earned a Grade A with Distinction under the supervision of Prof. V. Kotsis.
  • Master of Science in Research Methodology in Medicine and Health Science (2016-2018) – Achieved an outstanding 9/10 grade.
  • Research Fellowship (2019-2020) – Conducted clinical and research work in Diabetes Mellitus and Obesity at the University of Birmingham, UK.
  • Postdoctoral Research (2019-2022) – Specialized in Hypertension and Metabolic Syndrome at Aristotle University of Thessaloniki.
  • Internal Medicine Consultant Certification (2021) – Earned after passing rigorous written and oral examinations.

💼 PROFESSIONAL ENDEAVORS:

Dr. Antza has held various prestigious roles in internal medicine, focusing on hypertension, metabolic syndrome, and endocrinology:

  • Scientific Associate (2013-2014) – Engaged in research and clinical practice in hypertension at the 3rd Department of Internal Medicine, Aristotle University of Thessaloniki.
  • Medical Resident (2016-2021) – Trained at Papageorgiou General Hospital, Aristotle University of Thessaloniki.
  • Academic Fellowship in Hypertension & Metabolic Syndrome (2021-2022) – Focused on clinical practice, independent teaching, and research.
  • Internal Medicine Consultant (2021-2023) – Served at Papageorgiou General Hospital and Bioclinic, offering expertise in hypertension, diabetes, and emergency medicine.
  • Assistant Professor of Internal Medicine – Hypertension (2023-Present) – Currently educating future medical professionals and leading research at Aristotle University of Thessaloniki.

Additionally, she has participated as a Subinvestigator in Phase 2 & 3 Clinical Trials, contributing to advancements in hypertension and metabolic disorders.

📚 CONTRIBUTIONS AND RESEARCH FOCUS ON HYPERTENSION:

Dr. Antza has extensively researched hypertension, metabolic syndrome, diabetes, lipid disorders, and vascular aging. Her work has focused on:

  • Blood Pressure Measurement Techniques (Home, Ambulatory, and Clinical).
  • Atherosclerosis and Cardiovascular Risk.
  • Metabolic Syndrome and Obesity-Related Disorders.
  • Diabetes and Endocrine Disorders.

She has been actively involved in research collaborations with leading medical institutions, including Queen Elizabeth Hospital, Birmingham, UK, where she served as an Honorary Observer (2019-2022) in the Endocrinology Department.

🏆 IMPACT AND INFLUENCE:

Dr. Antza’s work has been recognized with numerous awards and fellowships:

  • Young Fellow of the European Atherosclerosis Society (2019-Present).
  • Young Fellow of the European Hypertension Society (2023-Present).
  • Recipient of multiple Investigator Grants & Travel Awards from the European Society of Hypertension (ESH) and European Atherosclerosis Society (EAS).
  • 1st Place Oral Presentation Award – 8th Panhellenic Congress of the Hellenic Atherosclerosis Society (2019).
  • 2nd Clinical Research Award – 9th Panhellenic Congress of the Hellenic Atherosclerosis Society (2020).
  • Young Investigator Fellowship Award – 89th EAS Virtual Congress (2021).

📖 ACADEMIC CITATIONS & SCHOLARSHIPS:

Dr. Antza’s research has been widely cited in medical literature, influencing clinical guidelines in hypertension and metabolic diseases. Her scholarly excellence has earned her:

  • Ph.D. Scholarship from the Hellenic Society of Atherosclerosis (2014-2015).
  • Postdoctoral Research Scholarship from the State Scholarship Foundation (2019-2021).
  • Award from the Medical Sciences Deanery for Ph.D. Research (2020).

🌍 LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Christina Antza is poised to make significant future contributions in the diagnosis and management of hypertension, metabolic syndrome, and cardiovascular diseases. Her expertise in clinical research, education, and innovative treatment strategies will continue to shape internal medicine and patient care.

Her future goals include:
✔ Expanding research on hypertension-related complications and vascular aging.
✔ Leading international collaborations in cardiovascular and metabolic diseases.
✔ Mentoring the next generation of medical professionals and researchers.
✔ Contributing to global guidelines on hypertension and cardiovascular risk management.

Her dedication to patient care, research, and teaching makes her an influential figure in modern internal medicine and hypertension research.

🌟CONCLUSION :

Assist. Prof. Dr. Christina Antza is a dedicated clinician, researcher, and educator in the fields of hypertension, metabolic syndrome, and internal medicine. With a strong academic foundation, international research collaborations, and numerous accolades, she continues to advance medical knowledge and improve patient care. Her contributions to medical education and research have made a lasting impact, inspiring future generations of physicians. As she progresses in her career, Dr. Antza remains committed to innovation, scientific discovery, and excellence in healthcare, shaping the future of cardiovascular and metabolic disease management. Her work stands as a testament to dedication and expertise.

TOP NOTABLE PUBLICATIONS

Clinic, Ambulatory and Home Blood Pressure Monitoring for Metabolic Syndrome: Time to Change the Definition?

Journal: Medicina

Year: 2025

The Microbial Perspective: A Systematic Literature Review on Hypertension and Gut Microbiota

Journal: Nutrients

Year: 2024

The Effects of Olive Oil Consumption on Biochemical Parameters and Body Mass Index of People with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal: Nutrients

Year: 2024

Familial Hypercholesterolemia in the Elderly: An Analysis of Clinical Profile and Atherosclerotic Cardiovascular Disease Burden from the Hellas-FH Registry

Journal: Biomedicines

Year: 2024

The Modern Environment: The New Secondary Cause of Hypertension?

Journal: Medicina

Year: 2023

The Importance of Out-of-Office Blood Pressure Measurement, as Highlighted by the Correlation with Left Ventricular Hypertrophy in an Untreated Hypertensive Population

Journal: Medicina

Year: 2023

Wei Zhang | Pharmacology | Best Researcher Award

Posted on by Pencis

Mr. Wei Zhang | Pharmacology | Best Researcher Award

Mr. Wei Zhang, Central South University, China

Mr. Wei Zhang is a Professor of Clinical Pharmacology at Central South University, China. He earned his Ph.D. in Pharmacology in 2006 under Prof. Hong-Hao Zhou. With expertise in pharmacogenomics, drug metabolism, and clinical trials, he has led major research projects, including personalized therapy and pharmacogenomic studies in diabetes. Zhang has served as Associate Dean of the Institute of Clinical Pharmacology and has been recognized with prestigious awards like the “New Century Excellent Talents” and “Henry Fok Young Teacher Award.” His research has significantly influenced precision medicine, enhancing drug efficacy and safety through genetic insights.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

🎓EARLY ACADEMIC PURSUITS:

Mr. Wei Zhang embarked on his academic journey at Central South University, China. He demonstrated a strong commitment to pharmacology and clinical medicine from an early stage:

  • Ph.D. in Pharmacology (2003-2006) – Under the supervision of Prof. Hong-Hao Zhou, a distinguished member of the China Engineering Academy, he specialized in clinical pharmacology, drug assay, pharmacokinetics, and pharmacodynamics.
  • M.A. in Pharmacology (2001-2003) – Focused on clinical pharmacology and pharmacogenomics, with practical expertise in human DNA pyrosequencing and drug metabolism.
  • B.A. in Clinical Medicine (1996-2001) – Gained foundational knowledge in pharmacology, physiology, pathology, and clinical medicine at XiangYa Medical School.

🏅PROFESSIONAL ENDEAVORS:

Throughout his career, Mr. Zhang has held significant academic and administrative roles at Central South University, contributing to the advancement of clinical pharmacology:

  • Professor (2013-Present) – Department of Clinical Pharmacology, Central South University.
  • Associate Dean (2009-Present) – Institute of Clinical Pharmacology.
  • Visiting Scholar (2012-2013) – University of Maryland, USA, exploring cutting-edge pharmaceutical research.
  • Head of Genetic Testing Laboratory (2007-2013) – Pioneered pharmacogenomic analysis.
  • Associate Professor (2008-2013) & Lecturer (2006-2008) – Focused on research and teaching in pharmacology.
  • Scientific Secretary (2005-Present) – National Key Discipline of Pharmacology, managing national-level research initiatives.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACOLOGY:

Mr. Zhang has led groundbreaking pharmacogenomics research, focusing on drug metabolism, personalized medicine, and renal drug toxicity. He has been a Principal Investigator (PI) in numerous national projects, including:

  • Pharmacogenomics Research on Type 2 Diabetes (2016-2019) – National Natural Science Foundation of China.
  • Multidrug Resistance Protein 2 (MRP2) & Cisplatin Nephrotoxicity (2013-2015) – Investigating genetic variations affecting renal drug accumulation.
  • Personalized Therapy via Pharmacogenetic Biomarkers (2012-2016) – National High Technology Research & Development Program (863 Program).
  • OATP1B1 Modulators & Mechanisms (2009-2011) – Studied drug transport mechanisms in human liver cells.
  • Pharmacogenomics in Drug Development (2009-2010) – Contributed to the national push for innovative drug research in China.

🌏IMPACT AND INFLUENCE:

As a global thought leader, Mr. Zhang has actively participated in international conferences and academic collaborations, including:

✅ Keynote Speaker & Presenter at pharmacogenetics conferences in China, Korea, Hong Kong, and the USA.
✅ Chairperson at the Cross-Strait Symposium on Pharmacogenomics (2012).
✅ Presenter at AAPS Annual Meeting (2013, USA).
✅ Collaborations with leading global research institutions.

His research has significantly influenced precision medicine and drug safety protocols, enhancing clinical trial methodologies worldwide.

🏆ACADEMIC CITES AND RECOGNITION:

Mr. Zhang’s academic excellence has been recognized through numerous awards and scholarships:

Class I Scholarship, Central South University (2004, 2005).
Outstanding Postgraduate Student Award (2004, 2005).
Excellent Report Award, Chinese Pharmacological Society (2005).
Outstanding Graduate of Central South University (2006).
“New Century Excellent Talents” Award, Ministry of Education (2010).
Science & Technology Prize, Chinese Society of Pharmacy (2010).
China Scholarship Council Foreign Fund (2012).
Outstanding Young Talents Award, China (2013).
Henry Fok Young Teacher Award (2014).

These accolades underscore his significant contributions to pharmacology and clinical research.

🔮LEGACY AND FUTURE CONTRIBUTIONS:

Mr. Zhang’s pioneering research in pharmacogenomics and clinical pharmacology has laid a strong foundation for:

  • Advancements in Personalized Medicine – Tailoring drug therapies based on genetic profiles.
  • Improved Drug Safety & Efficacy – Minimizing adverse drug reactions through genomic insights.
  • Mentorship & Academic Leadership – Training the next generation of pharmacologists and medical researchers.
  • Innovative Drug Development Strategies – Enhancing China’s pharmaceutical industry through precision medicine.

His vision for the future includes expanding global collaborations, leveraging AI in pharmacogenomics, and fostering next-generation clinical trials to revolutionize drug development and patient care.

🌟CONCLUSION:

Mr. Wei Zhang has made remarkable contributions to the field of clinical pharmacology and pharmacogenomics. His extensive research on personalized medicine, drug metabolism, and genetic biomarkers has advanced precision medicine, improving drug efficacy and safety. As a dedicated educator, researcher, and leader, he has mentored future scientists while holding key academic positions. His impactful work continues to shape the future of pharmacological research and healthcare innovation. With numerous accolades and groundbreaking studies, his legacy will inspire generations to come, driving advancements in drug development and individualized therapy.

TOP NOTABLE PUBLICATIONS

Title: The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals

Authors: L. Wang, B. Yu, Y. Peng, H. Zhou, J. Yin

Journal: Innovation

Year: 2025

Title: Astragali Radix-Angelicae Sinensis Radix inhibits the activation of vascular adventitial fibroblasts and vascular intimal proliferation by regulating the TGF-β1/Smad2/3 pathway

Authors: W. Li, S. Xu, L. Chen, W. Zhang, C. Deng

Journal: Journal of Ethnopharmacology

Year: 2025

Title: Metabolic characteristics of saponins from Panax notoginseng leaves biotransformed by gut microbiota in rats

Authors: J. Liu, L. Shao, J. Zhou, W. Huang

Journal: Analytical Methods

Year: 2025

Title: Hypoglycemic Effect of Ginsenoside Compound K Mediated by N-Acetylserotonin Derived From Gut Microbiota

Authors: S.T.Z. Huang, Y.H. Hu, Y. Gao, W. Zhang, W. Huang

Journal: Phytotherapy Research

Year: 2025

Title: Antitumor potentials of onco-microbial in Chinese patients with pancreatic cancer

Authors: Y. Gao, D. Zhou, Y. Lu, W. Huang, W. Zhang

Journal: Heliyon

Year: 2024

Title: OSGEP regulates islet β-cell function by modulating proinsulin translation and maintaining ER stress homeostasis in mice

Authors: Y. Liu, X. Yang, J. Zhou, H. Zhou, Q. Li

Journal: Nature Communications

Year: 2024

Title: Promoting remyelination in central nervous system diseases: Potentials and prospects of natural products and herbal medicine

Authors: H. Zhu, E. Hu, X. Guo, Y. Wang, T. Li

Journal: Pharmacological Research

Year: 2024

Title: Formononetin alleviates no reflow after myocardial ischemia-reperfusion via modulation of gut microbiota to inhibit inflammation

Authors: Y. Zhang, J. Deng, T. Chen, Z. Guo, W. Zhang

Journal: Life Sciences

Year: 2024

Title: Mime: A flexible machine-learning framework to construct and visualize models for clinical characteristics prediction and feature selection

Authors: H. Liu, W. Zhang, Y. Zhang, S.Y. Wanggou, X. Li

Journal: Computational and Structural Biotechnology Journal

Year: 2024

QIU SUN | Vascular disease | Best Researcher Award

Posted on by Pencis

Mr. QIU SUN | Vascular disease | Best Researcher Award

Mr. QIU SUN, Heilongjiang University of Chinese Medicine, China

Mr. Qiu Sun is the Director of the Department, Chief Physician, Associate Professor, and a Ph.D. candidate at Heilongjiang University of Chinese Medicine, China. A recognized expert in Traditional Chinese Medicine (TCM), he is a National Academic Successor and policy advisor in TCM healthcare. He has led multiple research projects, published SCI-indexed papers, and contributed to national textbooks. With two invention patents and numerous awards, he plays a key role in TCM education, clinical practice, and policy-making. His work focuses on integrative medicine, vascular diseases, and external treatments, making a significant impact on TCM’s modernization and global recognition.

AUTHOR PROFILE

Scopus Profile

🎓 EARLY ACADEMIC PURSUITS:

Mr. Sun Qiu was born in June 1982 and pursued his medical education at Heilongjiang University of Chinese Medicine, graduating in June 2009. His academic journey in Traditional Chinese Medicine (TCM) was marked by dedication to both theoretical and clinical practice. Currently, he is a Ph.D. candidate, continuously expanding his expertise in integrative medicine while mentoring future medical professionals as a Master’s Supervisor.

🏥 PROFESSIONAL ENDEAVORS:

As the Director of the Department, Chief Physician, and Associate Professor, Sun Qiu plays a crucial role in shaping TCM medical practices. His extensive responsibilities include supervising medical teams, enhancing healthcare quality, and pioneering innovative treatment methodologies. His leadership has significantly contributed to policy development in TCM hospitals across Heilongjiang Province.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON VASCULAR DISEASE:

Mr. Sun Qiu has been actively involved in various high-impact research projects, including:

  • Principal Investigator for 1 provincial-level project, 3 department-level projects, and 2 university-level projects
  • Participant in a National Natural Science Foundation of China (NSFC) project
  • Published 2 SCI-indexed papers and over 20 other research papers
  • Editor, co-editor, or contributor to 8 published books, exceeding 700,000 words
  • Holds 2 invention patents, reflecting his innovative contributions to TCM

His research primarily focuses on integrated traditional Chinese and Western medicine surgery, vascular diseases, and external treatment techniques in TCM.

🌍 IMPACT AND INFLUENCE:

Mr. Sun Qiu’s influence extends beyond clinical practice into policy-making and education. His key roles include:

  • National Academic Successor of Key Clinical Specialties in TCM
  • Expert in the Traditional Chinese Medicine Policy Think Tank
  • National Expert for the Supervision of TCM Statistical Data Quality
  • Project Review Expert for Science and Technology Departments in Sichuan, Anhui, and Guangxi Provinces

His editorial contributions to the “14th Five-Year Plan” National Textbook showcase his commitment to shaping the future of TCM education.

📚 ACADEMIC CITES & JOURNAL CONTRIBUTIONS:

Mr. Sun Qiu is an esteemed peer reviewer for international and national journals, including:

  • Scientific Reports (UK)
  • BMC Gastroenterology
  • Clinical Epigenetics
  • Chinese Health Preservation
  • China Contemporary Medicine

His role as a reviewer ensures high-quality research in TCM and integrative medicine.

🏆 LEGACY AND FUTURE CONTRIBUTIONS:

Mr. Sun Qiu has received numerous prestigious awards, including:

  • Second Prize from the Heilongjiang Provincial Government
  • First Prize from the Heilongjiang Administration of Traditional Chinese Medicine
  • Advanced Individual of the National TCM Monitoring and Statistics Expert Advisory Committee
  • Outstanding Communist Party Member
  • Excellence in Teaching & Advanced Educator Awards

With his extensive contributions to TCM policy, research, and education, Sun Qiu’s legacy continues to inspire medical professionals. His future endeavors aim at advancing integrative medicine and fostering global collaboration in TCM research.

🌟 CONCLUSION:

Mr. Qiu Sun is a pioneering force in Traditional Chinese Medicine (TCM), blending innovation with time-honored medical wisdom. His contributions to research, education, and policy-making have significantly shaped the future of integrative medicine. With numerous awards, patents, and publications, he continues to inspire the next generation of TCM professionals. As a leader in clinical excellence and academic advancements, his work plays a vital role in modernizing TCM and expanding its global influence. His dedication ensures that Traditional Chinese Medicine thrives in the 21st century and beyond!

TOP NOTABLE PUBLICATION

The association between serum copper concentration and prevalence of diabetes among US adults with hypertension (NHANES 2011–2016)

Authors: Kaiming Wu, Lixia Chen, Yanyan Kong, Jian-Feng Zhuo, Sun Qiu, Jianfei Chang

Journal: Journal of Cellular and Molecular Medicine

Year: 2024

Dong MA | Cardiovascular Researches | Best Researcher Award

Posted on by Pencis

Prof. Dong MA | Cardiovascular Researches | Best Researcher Award

Prof. Dong MA, Hebei Medical University, China

Prof. Dong Ma is a distinguished professor at Hebei Medical University, China, specializing in medical sciences and healthcare innovations. With a strong academic background, he has made significant contributions to biomedical research, clinical studies, and medical advancements. His work focuses on developing new treatments, improving patient care, and enhancing healthcare methodologies. Prof. Ma’s research is widely cited in prestigious medical journals, influencing global healthcare policies and practices. As a mentor and scholar, he continues to inspire future medical professionals while fostering international research collaborations. His dedication to medical excellence and innovation ensures a lasting impact in the field.

AUTHOR PROFILE

Scopus Profile

🎓 EARLY ACADEMIC PURSUITS:

Prof. Dong Ma embarked on his academic journey with a strong foundation in medical sciences. He pursued his education in China, demonstrating exceptional aptitude in the field of medicine and research. His early academic years were marked by rigorous studies, participation in innovative projects, and a keen interest in medical advancements.

🏛️ PROFESSIONAL ENDEAVORS:

Prof. Ma is currently a distinguished professor at Hebei Medical University, China. Throughout his career, he has been actively involved in teaching, mentoring, and guiding students in medical sciences. His professional engagements extend beyond the classroom, contributing to the university’s research and global collaborations in medical research and healthcare advancements.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR RESEARCHES:

Prof. Ma’s research primarily revolves around medical sciences, healthcare innovations, and clinical applications. His work includes:

  • Biomedical Research: Investigating novel treatments and technologies in the medical field.
  • Clinical Studies: Conducting evidence-based research to improve patient care and treatment outcomes.
  • Medical Innovations: Developing and contributing to new methodologies and technologies in healthcare.

His dedication to research has significantly impacted both theoretical knowledge and practical medical applications, benefiting healthcare professionals and patients alike.

🌍 IMPACT AND INFLUENCE:

Prof. Ma’s contributions have made a profound impact on the medical community. His research has been cited extensively in academic journals, influencing policies and practices in the field of medicine. His work has also led to collaborations with international medical institutions, further amplifying his influence on global healthcare development.

📖 ACADEMIC CITATIONS:

Prof. Ma has been cited in numerous prestigious medical journals and research papers. His publications cover a wide range of topics, including:

  • Advances in medical treatments and techniques.
  • Healthcare policy improvements.
  • Breakthroughs in disease prevention and management.

His academic work serves as a valuable resource for researchers, scholars, and healthcare professionals worldwide.

🏅 LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Dong Ma’s legacy is built upon his relentless pursuit of medical excellence. His future contributions are expected to:

  • Drive Innovation: Further enhance medical technologies and treatment approaches.
  • Inspire Future Scholars: Mentor upcoming medical professionals and researchers.
  • Expand Global Collaborations: Strengthen research ties with international institutions for broader healthcare advancements.

🔥 CONCLUSION:

Prof. Dong Ma stands as a visionary leader in medical sciences, shaping the future of healthcare through groundbreaking research, innovation, and education. His dedication to improving patient care, advancing medical treatments, and mentoring future professionals has left a lasting impact on both academia and clinical practice. With numerous contributions to medical research and extensive collaborations worldwide, he continues to drive progress in healthcare. His legacy is defined by excellence, knowledge, and a passion for medical advancements, ensuring a brighter, healthier future for generations to come.

TOP NOTABLE PUBLICATIONS

The Impact of the Monocyte-to-High-Density Lipoprotein Cholesterol Ratio on the Prognosis of Patients with Non-Viral,Non-Alcoholic Hepatocellular Carcinoma:a Retrospective Cohort Study

Authors: Xianzhe Lou, Tongguo Miao, Shiya Zhang, Dong Ma, Yuemin Nan

Journal: Chinese General Practice

Year: 2025

Combined DeRitis ratio and alkaline phosphatase on the prediction of portal vein tumor thrombosis in patients with hepatocellular carcinoma

Authors: Tongguo Miao, Shiya Zhang, Yunjing Zhang, Dong Ma, Yuemin Nan

Journal: Scientific Reports

Year: 2024

Study on the relationship between Methylation of Neuregulin (NRG) Gene and Cervical Carcinoma

Authors: Xizhao Yan, Fenglan An, Zhenzhen Ding, Dong Ma, Xiaohui Yang

Journal: Pakistan Journal of Medical Sciences

Year: 2024

α-HBDH is a superior to LDH in predicting major adverse cardiovascular events in patients with acute aortic dissection

Authors: Yunjing Zhang, Yue Sun, Yongbo Zhao, Dong Ma

Journal: Heliyon

Year: 2024

Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Hepatocellular Carcinoma in Patients with Metabolic-Associated Fatty Liver Disease

Authors: Tongguo Miao, Xianzhe Lou, Shiming Dong, Dong Ma, Yuemin Nan

Journal: Journal of Hepatocellular Carcinoma

Year: 2024

Boyoung Park | Epidemiology | Best Researcher Award

Posted on by Pencis

Prof. Boyoung Park | Epidemiology | Best Researcher Award

Prof. Boyoung Park, Hanyang University College of Medicine, South Korea

Professor Boyoung Park is a distinguished expert in preventive medicine, currently serving at Hanyang University College of Medicine in Seoul, South Korea. She leads the Bio-Big Data Center at the Hanyang Institute of Bioscience and Biotechnology. Her research, focusing on breast cancer risk factors and epidemiology, has been published in reputable journals such as the British Journal of Cancer and BMJ Open. In 2023, she was honored with the Kwangdong Cancer Academic Award by the Korean Cancer Association. Additionally, she contributes to the academic community as a senior editor for the Journal of Preventive Medicine & Public Health.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

🎓 EARLY ACADEMIC PURSUITS:

Professor Boyoung Park embarked on her medical education at the Catholic University of Daegu, where she earned her M.D. in 2006. Her passion for preventive medicine led her to Seoul National University College of Medicine, where she obtained her M.S. in 2010 and subsequently completed her Ph.D. in 2012. This strong academic foundation set the stage for her future contributions to epidemiology and cancer research.

💼 PROFESSIONAL ENDEAVORS:

Prof. Park’s career trajectory has been marked by prestigious positions in both academia and research institutions:

  • Director of the Bio-BigData Center at the Hanyang Institute of Bioscience and Biotechnology (2024–present)
  • Professor at the Department of Preventive Medicine, Hanyang University College of Medicine (2023–present)
  • Associate Professor at Hanyang University College of Medicine (2018–2023)
  • Assistant Professor at the National Cancer Center Graduate School of Cancer Science and Policy (2015–2018)
  • Associate Scientist at the National Cancer Control Institute, National Cancer Center (2012–2018)
  • Fellowship at the National Cancer Control Institute, National Cancer Center (2011–2012)
  • Residency in Preventive Medicine at Seoul National University College of Medicine (2008–2011)
  • Internship at Asan Medical Center, Seoul (2006–2007)

Her experience spans clinical practice, research, and academic leadership, demonstrating her commitment to advancing public health and epidemiology.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON EPIDEMIOLOGY:

Prof. Park has played a crucial role in cancer epidemiology, HIV research, and the development of disease risk assessment models. Her research interests include:

  • Cancer prevention and control
  • HIV/AIDS and chronic infectious diseases
  • Big data and epidemiological studies
  • Genome analysis and risk assessment models

🏆 RESEARCH GRANTS:

She has led multiple nationally funded projects, including:

  • Korea HIV/AIDS Cohort Study (2023–2024) – Principal Investigator
  • Korea Atomic Bomb Survivors Cohort and Genome Analysis (2020–2024) – Principal Investigator
  • Development of a Breast Cancer Risk Assessment Model (2021–2025) – Principal Investigator
  • Transfusion and Prognosis in Hepatobiliary & Pancreatic Surgery (2022–2025) – Principal Investigator

🏅 IMPACT AND INFLUENCE:

Prof. Park’s work has been widely recognized through prestigious awards and honors, such as:

  • National AIDS and STI Contributor Award (2023) – Korea Disease Control and Prevention Agency
  • Kwangdong Cancer Academic Award (2023) – Korean Cancer Association
  • Outstanding Paper Review Committee Award (2022) – Korean Society of Epidemiology
  • Excellent Researcher Award (2021) – Hanyang University
  • Young Epidemiologist Award (2015) – Korean Society of Epidemiology

📖 ACADEMIC CITATIONS AND EDITORIAL CONTRIBUTIONS:

Prof. Park serves as a Senior Editor and Editorial Board Member for leading medical journals:

  • Journal of Preventive Medicine & Public Health (Senior Editor)
  • Cancer Research and Treatment (Editorial Board Member)
  • Journal of Cancer Prevention (Editorial Board Member)

Her contributions to medical literature have significantly shaped the fields of epidemiology and public health.

🔮 LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Boyoung Park has established herself as a leading figure in preventive medicine and cancer epidemiology. Moving forward, she aims to:
 Advance big data-driven epidemiological research
Enhance public health policies for cancer prevention
Develop personalized risk assessment models for chronic diseases
Strengthen national and global health collaborations

Her groundbreaking work continues to shape the future of epidemiology, public health, and medical research in South Korea and beyond.

🌍CONCLUSION:

Professor Boyoung Park has made significant contributions to preventive medicine, epidemiology, and cancer research. As the Director of the Bio-Big Data Center at Hanyang University, her work in breast cancer risk assessment and public health continues to shape medical advancements. Recognized with prestigious awards, including the Kwangdong Cancer Academic Award, she remains a leading figure in medical research. Through her editorial roles and government advisory positions, she influences healthcare policies and scientific discourse. Her legacy will inspire future researchers and improve global public health outcomes.

TOP NOTABLE PUBLICATIONS

Economic Evaluation of Mass Screening as a Strategy for Hepatitis C Virus Elimination in South Korea

Authors: Hwa-young Choi, Kyung-ah Kim, Boyoung Park, Bo-youl Choi, Moran Ki

Journal: Journal of Infection and Public Health

Year: 2025

Korean Patients with Hereditary Cancer: A Prospective Multicentre Cohort Study Protocol Exploring Psychosocial and Health Outcomes

Authors: Jun-kyu Kim, Mi-Ae Jang, Jong-eun Park, Boyoung Park, Sun-young Kong

Journal: BMJ Open

Year: 2025

Associations Between Breastfeeding and Breast Cancer Risk Through Mammographic Breast Density in a Cohort of Korean Women

Authors: Soyeoun Kim, Thi Xuan Mai Tran, Mi-kyung Kim, Woojoo Lee, Boyoung Park

Journal: International Journal of Epidemiology

Year: 2025

Concordant and Discordant Breast Density Patterns by Different Approaches for Assessing Breast Density and Breast Cancer Risk

Authors: Yoosun Cho, Eunkyung Park, Yoosoo Chang, Shinho Kook, Seungho Ryu

Journal: Breast Cancer Research and Treatment

Year: 2025

A National Estimate of Mental Disorders and Mortality Outcomes in Cancer Survivors

Authors: Thi Xuan Mai Tran, Minsung Chung, Boyoung Park

Journal: Cancer

Year: 2025

Refining Breast Cancer Genetic Risk and Biology Through Multi-Ancestry Fine-Mapping Analyses of 192 Risk Regions

Authors: Guochong Jia, Zhishan Chen, Jie Ping, Jirong Long, Wei Zheng

Journal: Nature Genetics

Year: 2025

Carrier Frequency and Incidence of MUTYH-Associated Polyposis Based on Database Analysis in East Asians and Koreans

Authors: Jong-eun Park, Taeheon Lee, Eun-hye Cho, Chang-Seok Ki, Sun-young Kong

Journal: Annals of Laboratory Medicine

Year: 2025

Correction to: Height and Breast Cancer Risk in Premenopausal Korean Women Aged Under 40 Years of Age

Authors: Thi Xuan Mai Tran, Yoosoo Chang, Hye-rin Choi, Seungho Ryu, Boyoung Park

Journal: British Journal of Cancer

Year: 2024

Height and Breast Cancer Risk in Premenopausal Korean Women Aged Under 40 Years of Age: Epidemiology

Authors: Thi Xuan Mai Tran, Yoosoo Chang, Hye-rin Choi, Seungho Ryu, Boyoung Park

Journal: British Journal of Cancer

Year: 2024

Epidemiological Characteristics of HIV-Infected Individuals by the Registration for Special Exempted Calculation: A Nationwide Cohort Study

Authors: Yunsu Choi, Kyoung-hwan Ahn, Soomin Kim, Yoonhee Jun, Boyoung Park

Journal: Infection and Chemotherapy

Year: 2024

Zhihui Zhang | Cardiovascular Research | Best Researcher Award

Posted on by Pencis

Prof. Zhihui Zhang | Cardiovascular Research | Best Researcher Award

Prof. Zhihui Zhang, Army Medical University, China

Prof. Zhihui Zhang is a distinguished researcher at Army Medical University, China, specializing in cardiovascular diseases and stem cell therapy. His work focuses on endothelial seed cells, myocardial infarction, and immunosuppressive capabilities of mesenchymal stem cell-derived extracellular vesicles. He has published extensively in leading journals such as Genes and Diseases, Science Bulletin, and Stem Cell Research and Therapy. Prof. Zhang’s research contributes to advancing early diagnosis and targeted interventions for coronary microvascular dysfunction. His expertise in molecular biology and regenerative medicine has made significant impacts in cardiovascular research and clinical applications.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Zhihui Zhang embarked on his academic journey with a deep passion for cardiovascular medicine. His early education laid a strong foundation in medical sciences, leading him to specialize in cardiology. His dedication and excellence in research and clinical practice positioned him for advanced studies and significant contributions to the field.

🏥PROFESSIONAL ENDEAVORS:

Dr. Zhang is the Director of the Department of Cardiology at the First Affiliated Hospital (Southwest Hospital) of the Army Medical University in Chongqing. His leadership extends beyond the hospital as he holds multiple prestigious roles:

  • Member of the Great Vessel Group under the Cardiology Branch of the Chinese Medical Association
  • Member of the Cardiologists’ Association of the Chinese Medical Doctor Association
  • Deputy Director of the Committee for Structural Heart Disease under the China Human Health Promotion Association
  • Deputy Director of the Cardiology Branch of the Chongqing Medical Association, leading the Interventional Cardiology and Imaging Group

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR RESEARCH:

Dr. Zhang is renowned for his expertise in interventional treatment of coronary heart disease and structural heart disease. His research focuses on:

  • Precise diagnosis and treatment of coronary heart disease
  • Interventional therapy for valvular heart diseases
  • Establishing a cohort for precise classification of myocardial ischemia
  • Creating a biobank and an artificial intelligence center for coronary angiography physiological assessment

Additionally, he has developed the professional Circa Met DB database, specializing in metabolic circadian rhythms.

🌍IMPACT AND INFLUENCE:

Dr. Zhang’s contributions have earned him numerous accolades, including:
🏆 Two first prizes for scientific progress in Chongqing
🏆 One first prize for scientific progress in Hubei Province
🏆 One second prize for military medical achievements

He has successfully led over 20 research projects, ranging from national natural science funds to key military and Chongqing talent programs. His pioneering work in cardiology has influenced national and military healthcare policies.

📖ACADEMIC CITATIONS:

Dr. Zhang has an outstanding publication record, with more than 30 SCI papers as the first or corresponding author (including co-first/co-corresponding). His research has been featured in top-tier journals such as:
📌 The Lancet
📌 Nature Metabolism
📌 Nature Communications
📌 Trends in Cell Biology

Additionally, he has contributed to drafting and setting 12 expert consensus documents, served as a deputy editor for two monographs, and contributed to nine other books. His work extends to two national invention patents, further solidifying his impact in the field.

🚀LEGACY AND FUTURE CONTRIBUTIONS:

As a recipient of the Outstanding Youth Talent Fund in National Defense Bioscience, Dr. Zhang is recognized as a key innovator in cardiology. He has been honored as an Innovation Leading Talent by the Chongqing Talents Program and as a Science and Technology Talent by the Army.

His legacy will continue to shape the future of cardiovascular medicine through:
✅ Advanced research in interventional cardiology
✅ Expansion of AI-driven medical diagnostics
✅ Development of groundbreaking therapeutic techniques
✅ Mentorship and training of future cardiologists

🌟CONCLUSION:

Prof. Zhihui Zhang is a visionary leader in cardiology, blending clinical excellence, groundbreaking research, and technological innovation. His contributions have not only transformed patient care but also advanced global medical knowledge. His work will undoubtedly influence generations of medical professionals and redefine the future of cardiovascular treatment.

TOP NOTABLE PUBLICATIONS

Single nucleotide polymorphisms: Implications in the early diagnosis and targeted intervention of coronary microvascular dysfunction

Authors: Dingyuan Tian, Jie Li, Qingyuan Yang, Zhihui Zhang, Fang Deng

Journal: Genes and Diseases

Year: 2025

Circadian nutrition: is meal timing an elixir for fatigue?

Authors: Zhihui Zhang, Lu Yan, Jonas T. Treebak, Min-Dian Li

Journal: Science Bulletin

Year: 2025

Foxo1 drives the TGFβ1-dependent dichotomy of Th17 cell fates

Authors: Mengjuan Zhang, Yude Guan, Meijuan Han, Xiaomin Zhang, Song Zhang

Journal: Journal of Leukocyte Biology

Year: 2025

The short-term outcomes and risk factors of post-myocardial infarction ventricular septal rupture: a multi-center retrospective study

Authors: Wenjian Luo, Li Wen, Jinning Zhang, Zhexue Qin, Shiyong Yu

Journal: Journal of Cardiothoracic Surgery

Year: 2024

Sources and applications of endothelial seed cells: a review

Authors: Dan Deng, Yu Zhang, Bo Tang, Zhihui Zhang

Journal: Stem Cell Research and Therapy

Year: 2024

Enhanced immunosuppressive capability of mesenchymal stem cell-derived small extracellular vesicles with high expression of CD73 in experimental autoimmune uveitis

Authors: Yanan Duan, Xiteng Chen, Hui Shao, Jiawei Wang, Xiaomin Zhang

Journal: Stem Cell Research and Therapy

Year: 2024

Deciphering metabolic heterogeneity in retinoblastoma unravels the role of monocarboxylate transporter 1 in tumor progression

Authors: Junjie Tang, Yaoming Liu, Yinghao Wang, Ping Zhang, Rong Lu

Journal: Biomarker Research

Year: 2024

Associations between non-insulin-based insulin resistance indices and heart failure prevalence in overweight/obesity adults without diabetes mellitus: evidence from the NHANES 2001–2018

Authors: Diyu Cui, Chao Zhang, Yi Chen, Yu Zhang, Ping Zhu

Journal: Lipids in Health and Disease

Year: 2024

Single-cell transcriptomics enable the characterization of local extension in retinoblastoma

Authors: Yaoming Liu, Wei Hu, Yanjie Xie, Shengli Li, Rong Lu

Journal: Communications Biology

Year: 2024

Clinical characteristics of patients with moderate or severe valvular heart disease

Authors: Hao Gao, Yuzhu Lei, Haiyun Huang, Yanxiu Chen, Zhihui Zhang

Journal: Chinese Journal of Cardiology

Year: 2024